Basigin Promotes Cardiac Fibrosis and Failure in Response to Chronic Pressure Overload in Mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 4, 2016, Pages 636-646

  Suzuki, Kota ^a   Satoh, Kimio ^a   Ikeda, Shohei ^a   Sunamura, Shinichiro ^a   Otsuki, Tomohiro ^a   Satoh, Taijyu ^a   Kikuchi, Nobuhiro ^a   Omura, Junichi ^a   Kurosawa, Ryo ^a   Nogi, Masamichi ^a   Numano, Kazuhiko ^a   Sugimura, Koichiro ^a   Aoki, Tatsuo ^a   Tatebe, Shunsuke ^a   Miyata, Satoshi ^e   Mukherjee, Rupak ^b   Spinale, Francis G ^c   Kadomatsu, Kenji ^d   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e NONE

Author keywords

angiotensin II; cytokines; heart failure; hypertrophy; inflammation

Indexed keywords

CD147 ANTIGEN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; ANGIOTENSIN II; AUTACOID; BSG PROTEIN, HUMAN; BSG PROTEIN, MOUSE; BSG PROTEIN, RAT; PLASMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; HEART FAILURE; HEART FIBROBLAST; HEART MUSCLE FIBROSIS; HEART WEIGHT; LUNG WEIGHT; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; ANIMAL; AORTA DISEASE; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CELL CULTURE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; FIBROBLAST; FIBROSIS; GENETICS; HEART LEFT VENTRICLE FUNCTION; HYPERTROPHY, LEFT VENTRICULAR; KNOCKOUT MOUSE; MALE; MECHANOTRANSDUCTION; METABOLISM; NEWBORN; PATHOLOGY; PATHOPHYSIOLOGY; PREVENTION AND CONTROL; RAT; TIME FACTOR; WISTAR RAT;

ANGIOTENSIN II; ANIMALS; ANIMALS, NEWBORN; ANTIGENS, CD147; AORTIC DISEASES; BLOOD PROTEINS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; FIBROSIS; HEART FAILURE; HYPERTROPHY, LEFT VENTRICULAR; INFLAMMATION MEDIATORS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MATRIX METALLOPROTEINASES; MECHANOTRANSDUCTION, CELLULAR; MICE, KNOCKOUT; MYOCARDIUM; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84959255326     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.306686     Document Type: Article

References (53)

1. Roger VL. Epidemiology of heart failure. Circ Res. 2013;113:646-659.
2. Sharma K, Kass DA. Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res. 2014;115:79-96. doi: 10.1161/CIRCRESAHA.115.302922.
3. Oka T, Akazawa H, Naito AT, Komuro I. Angiogenesis and cardiac hypertrophy: maintenance of cardiac function and causative roles in heart failure. Circ Res. 2014;114:565-571. doi: 10.1161/CIRCRESAHA.114.300507.
4. Lyon RC, Zanella F, Omens JH, Sheikh F. Mechanotransduction in cardiac hypertrophy and failure. Circ Res. 2015;116:1462-1476. doi: 10.1161/ CIRCRESAHA.116.304937.
5. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol. 2006;7:589-600. doi: 10.1038/nrm1983.
6. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 2007;49:241-248. doi: 10.1161/01. HYP.0000254415.31362.a7.
7. Sugden PH. Ras, Akt, and mechanotransduction in the cardiac myocyte. Circ Res. 2003;93:1179-1192. doi: 10.1161/01.RES. 0000106132.04301.F5.
8. Molkentin JD. Calcineurin and beyond: cardiac hypertrophic signaling. Circ Res. 2000;87:731-738.
9. Ikeda S, Satoh K, Kikuchi N, Miyata S, Suzuki K, Omura J, Shimizu T, Kobayashi K, Kobayashi K, Fukumoto Y, Sakata Y, Shimokawa H. Crucial role of rho-kinase in pressure overload-induced right ventricular hypertrophy and dysfunction in mice. Arterioscler Thromb Vasc Biol. 2014;34:1260-1271. doi: 10.1161/ATVBAHA.114.303320.
10. Satoh K, Nigro P, Zeidan A, Soe NN, Jaffré F, Oikawa M, O'Dell MR, Cui Z, Menon P, Lu Y, Mohan A, Yan C, Blaxall BC, Berk BC. Cyclophilin A promotes cardiac hypertrophy in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2011;31:1116-1123. doi: 10.1161/ ATVBAHA.110.214601.
11. Asaumi Y, Kagaya Y, Takeda M, Yamaguchi N, Tada H, Ito K, Ohta J, Shiroto T, Shirato K, Minegishi N, Shimokawa H. Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation. 2007;115:2022-2032. doi: 10.1161/CIRCULATIONAHA.106.659037.
12. Iacono KT, Brown AL, Greene MI, Saouaf SJ. CD147 immunoglobulin superfamily receptor function and role in pathology. Exp Mol Pathol. 2007;83:283-295. doi: 10.1016/j.yexmp.2007.08.014.
13. Huet E, Vallée B, Szul D, Verrecchia F, Mourah S, Jester JV, Hoang- Xuan T, Menashi S, Gabison EE. Extracellular matrix metalloproteinase inducer/CD147 promotes myofibroblast differentiation by inducing alphasmooth muscle actin expression and collagen gel contraction: implications in tissue remodeling. FASEB J. 2008;22:1144-1154. doi: 10.1096/ fj.07-8748com.
14. Gou X, Ru Q, Zhang H, Chen Y, Li L, Yang H, Xing J, Chen Z. HAb18G/ CD147 inhibits starvation-induced autophagy in human hepatoma cell SMMC7721 with an involvement of Beclin 1 down-regulation. Cancer Sci. 2009;100:837-843. doi: 10.1111/j.1349-7006.2009.01113.x.
15. Satoh K, Satoh T, Kikuchi N, et al. Basigin mediates pulmonary hypertension by promoting inflammation and vascular smooth muscle cell proliferation. Circ Res. 2014;115:738-750. doi: 10.1161/ CIRCRESAHA.115.304563.
16. Seizer P, Ungern-Sternberg SN, Schönberger T, Borst O, Münzer P, Schmidt EM, Mack AF, Heinzmann D, Chatterjee M, Langer H, Malešević M, Lang F, Gawaz M, Fischer G, May AE. Extracellular cyclophilin A activates platelets via EMMPRIN (CD147) and PI3K/Akt signaling, which promotes platelet adhesion and thrombus formation in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2015;35:655-663. doi: 10.1161/ ATVBAHA.114.305112.
17. Crosnier C, Bustamante LY, Bartholdson SJ, Bei AK, Theron M, Uchikawa M, Mboup S, Ndir O, Kwiatkowski DP, Duraisingh MT, Rayner JC, Wright GJ. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature. 2011;480:534-537. doi: 10.1038/nature10606.
18. Tang W, Chang SB, Hemler ME. Links between CD147 function, glycosylation, and caveolin-1. Mol Biol Cell. 2004;15:4043-4050. doi: 10.1091/ mbc.E04-05-0402.
19. Agrawal SM, Yong VW. The many faces of EMMPRIN - roles in neuroinflammation. Biochim Biophys Acta. 2011;1812:213-219. doi: 10.1016/j. bbadis.2010.07.018.
20. Yan L, Zucker S, Toole BP. Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost. 2005;93:199-204. doi: 10.1160/TH04-08-0536.
21. Maeda-Hori M, Kosugi T, Kojima H, et al. Plasma CD147 reflects histological features in patients with lupus nephritis. Lupus. 2014;23:342-352. doi: 10.1177/0961203314520840.
22. Damsker JM, Okwumabua I, Pushkarsky T, Arora K, Bukrinsky MI, Constant SL. Targeting the chemotactic function of CD147 reduces collagen-induced arthritis. Immunology. 2009;126:55-62. doi: 10.1111/j.1365-2567.2008.02877.x.
23. Schmidt R, Bültmann A, Fischel S, Gillitzer A, Cullen P, Walch A, Jost P, Ungerer M, Tolley ND, Lindemann S, Gawaz M, Schömig A, May AE. Extracellular matrix metalloproteinase inducer (CD147) is a novel receptor on platelets, activates platelets, and augments nuclear factor kappaBdependent inflammation in monocytes. Circ Res. 2008;102:302-309. doi: 10.1161/CIRCRESAHA.107.157990.
24. Haug C, Lenz C, Díaz F, Bachem MG. Oxidized low-density lipoproteins stimulate extracellular matrix metalloproteinase Inducer (EMMPRIN) release by coronary smooth muscle cells. Arterioscler Thromb Vasc Biol. 2004;24:1823-1829. doi: 10.1161/01.ATV.0000142806.59283.11.
25. Lizarbe TR, Tarín C, Gómez M, Lavin B, Aracil E, Orte LM, Zaragoza C. Nitric oxide induces the progression of abdominal aortic aneurysms through the matrix metalloproteinase inducer EMMPRIN. Am J Pathol. 2009;175:1421-1430. doi: 10.2353/ajpath.2009.080845.
26. Miller LH, Ackerman HC, Su XZ, Wellems TE. Malaria biology and disease pathogenesis: insights for new treatments. Nat Med. 2013;19:156-167. doi: 10.1038/nm.3073.
27. Seizer P, Ochmann C, Schönberger T, Zach S, Rose M, Borst O, Klingel K, Kandolf R, MacDonald HR, Nowak RA, Engelhardt S, Lang F, Gawaz M, May AE. Disrupting the EMMPRIN (CD147)-cyclophilin A interaction reduces infarct size and preserves systolic function after myocardial ischemia and reperfusion. Arterioscler Thromb Vasc Biol. 2011;31:1377-1386. doi: 10.1161/ATVBAHA.111.225771.
28. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, Goldberg AT, Zellner JL, Crumbley AJ. A matrix metalloproteinase induction/ activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation. 2000;102:1944-1949.
29. Seizer P, Geisler T, Bigalke B, Schneider M, Klingel K, Kandolf R, Stellos K, Schreieck J, Gawaz M, May AE. EMMPRIN and its ligand cyclophilin A as novel diagnostic markers in inflammatory cardiomyopathy. Int J Cardiol. 2013;163:299-304. doi: 10.1016/j.ijcard.2011.06.049.
30. Higashikuni Y, Tanaka K, Kato M, Nureki O, Hirata Y, Nagai R, Komuro I, Sata M. Toll-like receptor-2 mediates adaptive cardiac hypertrophy in response to pressure overload through interleukin-1β upregulation via nuclear factor κB activation. J Am Heart Assoc. 2013;2:e000267. doi: 10.1161/JAHA.113.000267.
31. Baudino TA, Carver W, Giles W, Borg TK. Cardiac fibroblasts: friend or foe? Am J Physiol Heart Circ Physiol. 2006;291:H1015-H1026. doi: 10.1152/ajpheart.00023.2006.
32. Gulati A, Jabbour A, Ismail TF, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309:896-908. doi: 10.1001/jama.2013.1363.
33. Schiattarella GG, Hill JA. Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload. Circulation. 2015;131:1435-1447. doi: 10.1161/CIRCULATIONAHA.115.013894.
34. Laroumanie F, Douin-Echinard V, Pozzo J, Lairez O, Tortosa F, Vinel C, Delage C, Calise D, Dutaur M, Parini A, Pizzinat N. CD4+ T cells promote the transition from hypertrophy to heart failure during chronic pressure overload. Circulation. 2014;129:2111-2124. doi: 10.1161/ CIRCULATIONAHA.113.007101.
35. Zavadzkas JA, Plyler RA, Bouges S, Koval CN, Rivers WT, Beck CU, Chang EI, Stroud RE, Mukherjee R, Spinale FG. Cardiac-restricted overexpression of extracellular matrix metalloproteinase inducer causes myocardial remodeling and dysfunction in aging mice. Am J Physiol Heart Circ Physiol. 2008;295:H1394-H1402. doi: 10.1152/ajpheart.00346.2008.
36. Siwik DA, Kuster GM, Brahmbhatt JV, Zaidi Z, Malik J, Ooi H, Ghorayeb G. EMMPRIN mediates beta-adrenergic receptor-stimulated matrix metalloproteinase activity in cardiac myocytes. J Mol Cell Cardiol. 2008;44:210-217. doi: 10.1016/j.yjmcc.2007.07.054.
37. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, Cooke MP, Walker JR, Hogenesch JB. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A. 2004;101:6062-6067. doi: 10.1073/ pnas.0400782101.
38. Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J, Kikuchi M. Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int. 2006;56:359-367. doi: 10.1111/j.1440-1827.2006.01972.x.
39. Chen W, Frangogiannis NG. Fibroblasts in post-infarction inflammation and cardiac repair. Biochim Biophys Acta. 2013;1833:945-953. doi: 10.1016/j.bbamcr.2012.08.023.
40. Takeda N, Manabe I, Uchino Y, Eguchi K, Matsumoto S, Nishimura S, Shindo T, Sano M, Otsu K, Snider P, Conway SJ, Nagai R. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J Clin Invest. 2010;120:254-265. doi: 10.1172/JCI40295.
41. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456:980-984. doi: 10.1038/nature07511.
42. Kaushik DK, Hahn JN, Yong VW. EMMPRIN, an upstream regulator of MMPs, in CNS biology. Matrix Biol. 2015;44-46:138-146. doi: 10.1016/j. matbio.2015.01.018.
43. Sangboonruang S, Thammasit P, Intasai N, Kasinrerk W, Tayapiwatana C, Tragoolpua K. EMMPRIN reduction via scFv-M6-1B9 intrabody affects α3β1-integrin and MCT1 functions and results in suppression of progressive phenotype in the colorectal cancer cell line Caco-2. Cancer Gene Ther. 2014;21:246-255. doi: 10.1038/cgt.2014.24.
44. Dean NR, Newman JR, Helman EE, Zhang W, Safavy S, Weeks DM, Cunningham M, Snyder LA, Tang Y, Yan L, McNally LR, Buchsbaum DJ, Rosenthal EL. Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer. Clin Cancer Res. 2009;15:4058-4065. doi: 10.1158/1078-0432.CCR-09-0212.
45. Liu H, Yang LX, Guo RW, Zhu GF, Shi YK, Wang XM, Qi F, Guo CM, Ye JS, Yang ZH, Liang X. Functional blockage of EMMPRIN ameliorates atherosclerosis in apolipoprotein E-deficient mice. Int J Cardiol. 2013;168:3248-3253. doi: 10.1016/j.ijcard.2013.04.141.
46. Cao J, Han Z, Tian L, Chen K, Fan Y, Ye B, Huang W, Wang C, Huang Z. Curcumin inhibits EMMPRIN and MMP-9 expression through AMPKMAPK and PKC signaling in PMA induced macrophages. J Transl Med. 2014;12:266. doi: 10.1186/s12967-014-0266-2.
47. Huang Z, Wang L, Meng S, Wang Y, Chen T, Wang C. Berberine reduces both MMP-9 and EMMPRIN expression through prevention of p38 pathway activation in PMA-induced macrophages. Int J Cardiol. 2011;146:153-158. doi: 10.1016/j.ijcard.2009.06.023.
48. Venkatesan B, Valente AJ, Reddy VS, Siwik DA, Chandrasekar B. Resveratrol blocks interleukin-18-EMMPRIN cross-regulation and smooth muscle cell migration. Am J Physiol Heart Circ Physiol. 2009;297:H874-H886. doi: 10.1152/ajpheart.00311.2009.
49. Huang Z, Wang C, Wei L, Wang J, Fan Y, Wang L, Wang Y, Chen T. Resveratrol inhibits EMMPRIN expression via P38 and ERK1/2 pathways in PMA-induced THP-1 cells. Biochem Biophys Res Commun. 2008;374:517-521. doi: 10.1016/j.bbrc.2008.07.058.
50. Yanaba K, Asano Y, Tada Y, Sugaya M, Kadono T, Hamaguchi Y, Sato S. Increased serum soluble CD147 levels in patients with systemic sclerosis: association with scleroderma renal crisis. Clin Rheumatol. 2012;31:835-839. doi: 10.1007/s10067-012-1949-9.
51. Moonsom S, Tayapiwatana C, Wongkham S, Kongtawelert P, Kasinrerk W. A Competitive ELISA for quantifying serum CD147: reduction of soluble CD147 levels in cancer patient sera. Hybridoma (Larchmt). 2010;29:45-52. doi: 10.1089/hyb.2009.0096.
52. Nymo SH, Hulthe J, Ueland T, McMurray J, Wikstrand J, Askevold ET, Yndestad A, Gullestad L, Aukrust P. Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA. Eur J Heart Fail. 2014;16:68-75. doi: 10.1093/eurjhf/ hft125.
53. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005;112:1756-1762. doi: 10.1161/CIRCULATIONAHA.104.530972.